课题基金 / 基金详情

Selective non-carbohydrate GBA2 inhibitors and their evaluation in models of Batten Disease.

Selective non-carbohydrate GBA2 inhibitors and their evaluation in models of Batten Disease.
选择性非碳水化合物 GBA2 抑制剂及其在 Batten 病模型中的评估。
批准号：
462565
负责人：
Vocadlo David
金额：
$33.16万
依托单位：
Simon Fraser University (Burnaby, B.C.)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-03-01 至 2025-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=462565&lang=en
关键词：
Carbohydrates Enzymes Glycobiology High-Throughput Screening Inhibitors Medicinal Chemistry

项目摘要

项目成果

Vocadlo David的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Despite extensive efforts, there is only one clinically approved small molecule therapeutic that can slow the progression of any neurodegenerative disease. This compound is known as miglustat, and it is used to treat the rare orphan lysosomal disease know
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of proteostasis by glycosylation of nucleocytoplasmic proteins.
Regulation of cellular proteostasis by glycosylation of nucleocytoplasmic proteins.
Glycosylation of hydroxymethylcytosine in mammalian genomes - distribution and functional roles.
CANADA RESEARCH CHAIRHOLDER - Tier 1 / TITULAIRE DE CHAIRE DE RECHERCHE DU CANADA - Niveau 1
海外基金